BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dalton Pharma Services Announces Release of White Paper on Risk Sharing


12/3/2013 12:33:05 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(PRWEB) December 03, 2013 -- Dalton Pharma Services, a leading provider of drug discovery, development and manufacturing services to pharmaceutical and biotechnology companies, today announced that the company has released its white paper on Risk Sharing in Sponsor-CMO contracts.

In the white paper, entitled “Towards Equitable Risk Relationships: Views on Risk Sharing in Sponsor-CMO Contracts,” Peter Pekos, CEO of Dalton Pharma, shares his experiences and thoughts on a wide variety of risk sharing approaches Dalton Pharma Services has successfully utilized over the last 25 years. From materials management to IP rights, the paper addresses many aspects of risk that influence the structures of contracts and relationships with sponsors.

The full white paper is available for download on the Dalton website at http://www.dalton.com.

“In my experience, the most satisfactory contracts are those which bind the parties in a “joined at the hip” relationship,” said Peter Pekos, CEO of Dalton Pharma. “When we speak of contractual risk, we are looking for an alignment of risk and appropriate protections for both parties.”

About Dalton:

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a GMP contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

Further information can be found at http://www.dalton.com.

For further information, contact:

Peter Pekos

President & CEO

Dalton Pharma Services Inc.

349 Wildcat Road

Toronto, Ontario

Tel: 416-661-2102

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES